We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
IDT Presents at Presidential Commission for the Study of Bioethical Issues
News

IDT Presents at Presidential Commission for the Study of Bioethical Issues

IDT Presents at Presidential Commission for the Study of Bioethical Issues
News

IDT Presents at Presidential Commission for the Study of Bioethical Issues

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "IDT Presents at Presidential Commission for the Study of Bioethical Issues"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Appearing on behalf of the International Gene Synthesis Consortium (IGSC) member companies, Integrated DNA Technologies (IDT) has spoken at the Presidential Commission for the Study of Bioethical Issues, in Philadelphia, PA.

The IGSC represents approximately 80% of the worldwide gene synthesis capacity and has been working with the US and other governments to establish standards and practices to prevent the misuse of synthetic genes. Having taken a prominent role in the recent public policy discussion of the biosafety and biosecurity concerns relating to gene synthesis technology, IDT has helped to lead the development of the IGSC’s Harmonized Screening Protocol. The Commission invited IDT to its second public meeting to describe those efforts.

IDT’s Senior Vice President and General Counsel for International Legal and Regulatory Affairs, Damon Terrill, spoke about the screening standards and practices applied by all IGSC member companies, and their close collaboration with federal authorities. He discussed how the IGSC’s sequence and customer screening protocol achieves the objectives of the US Government’s draft Screening Framework Guidance for Synthetic Double-stranded DNA Providers1, and suggested supplementary measures to minimize the risks associated with the commercial availability of synthetic genes.

Also representing the IGSC, Dr. Ralph Wagner, CEO and CSO of Geneart, went on to talk about the broad range of synthetic biology applications, emphasizing the need to balance the risks presented by synthetic biology technology against its potentially revolutionary benefits.

IDT offers a complete, custom gene synthesis service, using the highest fidelity next generation synthesis technology. By providing codon optimization and sequence verification, 2 µg yields of purified, double-stranded DNA are guaranteed from every order. Users can choose between a broad range of standard or custom cloning vectors, and all sequence information remains secure and confidential.

In accordance with the IGSC’s Harmonized Screening Protocol, IDT screens the sequences of all ordered genes to identify regulated and other potentially dangerous pathogen sequences. In addition, IDT verifies that all customers are legitimate scientists engaged in beneficial research.
Advertisement